Policies on faculty conflicts of interest at US universities

被引:127
作者
Cho, MK
Shohara, R
Schissel, A
Rennie, D
机构
[1] Stanford Univ, Ctr Biomed Eth, Palo Alto, CA 94304 USA
[2] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA
[3] NYU, Sch Law, New York, NY 10003 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 284卷 / 17期
关键词
D O I
10.1001/jama.284.17.2203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Despite federal regulations on faculty conflicts of interest in federally funded research, academic-industry ties are common, and evidence exists that financial considerations bias the research record. Public scrutiny of these ties is increasing, especially in cases where researchers have financial interests in the corporate sponsors of their clinical research. Objective To review policies on conflict of interest at major biomedical research institutions in the United,States. Design Cross-sectional survey and content analysis study conducted from August 1998 to February 2000. Setting and Participants The 100 US institutions with the most funding from the National Institutes of Health in 1998 were initially sampled; policies from 89 institutions were available and included in the analysis. Main Outcome Measures Process for disclosure, review, and management of conflicts of interest and specified management strategies or limitations, according to the institutions' faculty/staff conflict of interest policies. Results Content of the conflict of interest policies varied widely across institutions. Fifty-five percent of policies (n=49) required disclosures from all faculty while 45% (n =40) required them only from principal investigators or those conducting research. Nineteen percent of policies (n=17) specified limits on faculty financial interests in corporate sponsors of research, 12% (n=11) specified limits on permissible delays in publication, and 4% (n=4) prohibited student involvement in work sponsored by a company in which the faculty mentor had a financial interest. Conclusions Most policies on conflict of interest in our sample of major research institutions in the United States lack specificity about the kinds of relationships with industry that are permitted or prohibited. Wide variation in management of conflicts of interest among institutions may cause unnecessary confusion among potential industrial partners or competition among universities for corporate sponsorship that could erode academic standards. It is in the long-term interest of institutions to develop widely agreed-on, clear, specific, and credible policies on conflicts of interest.
引用
收藏
页码:2203 / 2208
页数:6
相关论文
共 17 条
[1]  
[Anonymous], WASHINGTON POST
[2]   Influences on the quality of published drug studies [J].
Bero, LA ;
Rennie, D .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1996, 12 (02) :209-237
[3]   THE PUBLICATION OF SPONSORED SYMPOSIUMS IN MEDICAL JOURNALS [J].
BERO, LA ;
GALBRAITH, A ;
RENNIE, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (16) :1135-1140
[4]   Participation of life-science faculty in research relationships with industry [J].
Blumenthal, D ;
Campbell, EG ;
Causino, N ;
Louis, KS .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (23) :1734-1739
[5]   Withholding research results in academic life science - Evidence from a national survey of faculty [J].
Blumenthal, D ;
Campbell, EG ;
Anderson, MS ;
Causino, N ;
Louis, KS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (15) :1224-1228
[6]   Uneasy alliance - Clinical investigators and the pharmaceutical industry [J].
Bodenheimer, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1539-1544
[7]   The quality of drug studies published in symposium proceedings [J].
Cho, MK ;
Bero, LA .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (05) :485-+
[8]  
Eichenwald Kurt, 1999, N Y Times Web, pA16
[9]  
Krimsky S, 1996, Sci Eng Ethics, V2, P395, DOI 10.1007/BF02583927
[10]  
OHARROW R, 2000, WASHINGTON POST MAY, pA16